EASD Annual Meeting 2026: key results and trends

At week 32, HRS-7535 reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo (placebo-adjusted differences: −1.34%, −1.42%, and −1.62%, respectively; all p<0.0001) based on the efficacy estimand.

An HbA1c <7% (53 mmol/mol) was reached by 61% (3 mg), 81% (12 mg) and 69% (36 mg) of OFG-treated participants vs 24% in PBO (p<0.001).

The estimated mean change from BL in HbA1c was -1.7% (-18.5 mmol/mol) with 4 mg, -2.0% (-22.0 mmol/mol) with 9 mg, and -1.9% (-21.0 mmol/mol) with 12 mg retatrutide, compared to -0.8% (-8.5 mmol/mol) with placebo (all p<0.001).

At week 28, HbA1c was reduced by 1.38% in both TG103 15 mg and DULA groups from baseline, and the estimated treatment difference was 0.00% (95%CI: -0.19, 0.18), meeting the prespecified noninferiority criterion (margin 0.4%; one-sided p < 0.0001).

At week 24, the anagliptin group showed a significantly greater reduction in HbA1c compared to the placebo group (mean change: -0.74% ± 0.52 for Anagliptin vs. -0.30% ± 0.60 for placebo; p < 0.001).

While the risk of serious hyperkalemia was generally higher with finerenone vs placebo, overall incidence was low across HbA1c categories (normoglycemia: 0.6% vs 0.9%; prediabetes: 1.7% vs 0.3%; adequately controlled T2D: 1.0% vs 0.1%; inadequately controlled T2D: 1.1% vs 0.4%).

Pts receiving Olatorepatide 5 mg, 10 mg, or 15 mg compared with pbo had greater achievement of BW reductions of ≥5% (83.5%, 96.1%, 93.9% vs 31.0%), ≥10% (58.9%, 87.4%, 86.4% vs 15.0%), and ≥15% (31.8%, 57.4%, 67.3% vs 3.2%).

The incidence of treatment-emergent adverse events (TEAEs) for HDM1702 and reference semaglutide was 86.6% and 85.7%, respectively.

Non inferiority was confirmed for the primary endpoint for BCLIS: A1C was reduced by 0.65% (BCLIS) and 0.57% (LIS): estimated treatment difference of -0.07% [95% CI -0.18; 0.03].

Compared with placebo, cagrilintide 2.4 mg significantly reduced body weight (ETD −9.6% [−10.6, −8.5]; p<0.0001) and WHtR (ETD −0.04 [−0.05, −0.03]; p<0.0001).

In pts with resistant hypertension, mean SBP changes at week 72 were −7.8, −8.2 mmHg and −4.0 mmHg with semaglutide 7.2 mg, semaglutide 2.4 mg, and placebo, respectively.

A significantly higher proportion of participants achieved an HbA1c ≤7.0% with HDM1005 (69.2%, 86.5%, 83.3%, and 86.1%) compared to placebo (25.7%).